7 results on '"GLP-1 - glucagon-like peptide-1"'
Search Results
2. Case report: Nerve fiber regeneration in children with melanocortin 4 receptor gene mutation related obesity treated with semaglutide.
- Author
-
Gad H, Mohammed I, Dauleh H, Pasha M, Al-Barazenji T, Hussain K, and Malik RA
- Subjects
- Humans, Male, Female, Child, Glucagon-Like Peptides therapeutic use, Glucagon-Like Peptides pharmacology, Nerve Fibers drug effects, Nerve Fibers pathology, Mutation, Obesity drug therapy, Obesity genetics, Cornea drug effects, Cornea innervation, Cornea pathology, Pediatric Obesity drug therapy, Adolescent, Receptor, Melanocortin, Type 4 genetics, Nerve Regeneration drug effects
- Abstract
Melanocortin 4 receptor ( MC4R ) mutations are the commonest cause of monogenic obesity through dysregulation of neuronal pathways in the hypothalamus and prefrontal cortex that regulate hunger and satiety. MC4R also regulates neuropathic pain pathways via JNK signaling after nerve injury. We show evidence of corneal small fiber degeneration in 2 siblings carrying a heterozygous missense variant c.508A>G, p.Ille170Val in the MC4R gene. Both children were treated with once weekly semaglutide for 6 months with no change in weight, and only a minor improvement in HbA1c and lipid profile. However, there was evidence of nerve regeneration with an increase in corneal nerve fiber density (CNFD) [child A (13.9%), child B (14.7%)], corneal nerve branch density (CNBD) [child A (110.2%), child B (58.7%)] and corneal nerve fiber length (CNFL) [child A (21.5%), child B (44.0%)]., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Gad, Mohammed, Dauleh, Pasha, Al-Barazenji, Hussain and Malik.)
- Published
- 2024
- Full Text
- View/download PDF
3. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.
- Author
-
Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, Nawaz FK, Tracey K, Yang H, LeRoith D, Brownstein MJ, and Roth J
- Subjects
- Humans, Peptides therapeutic use, Inflammation drug therapy, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents therapeutic use, Glucagon-Like Peptide 1 therapeutic use, Glucagon-Like Peptide 1 metabolism, Diabetes Mellitus, Type 2 drug therapy
- Abstract
Inflammation contributes to many chronic conditions. It is often associated with circulating pro-inflammatory cytokines and immune cells. GLP-1 levels correlate with disease severity. They are often elevated and can serve as markers of inflammation. Previous studies have shown that oxytocin, hCG, ghrelin, alpha-MSH and ACTH have receptor-mediated anti-inflammatory properties that can rescue cells from damage and death. These peptides have been studied well in the past century. In contrast, GLP-1 and its anti-inflammatory properties have been recognized only recently. GLP-1 has been proven to be a useful adjuvant therapy in type-2 diabetes mellitus, metabolic syndrome, and hyperglycemia. It also lowers HbA1C and protects cells of the cardiovascular and nervous systems by reducing inflammation and apoptosis. In this review we have explored the link between GLP-1, inflammation, and sepsis., Competing Interests: Author MB was employed by Azevan Pharmaceuticals Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Mehdi, Pusapati, Anwar, Lohana, Kumar, Nandula, Nawaz, Tracey, Yang, LeRoith, Brownstein and Roth.)
- Published
- 2023
- Full Text
- View/download PDF
4. The complex involvement of the digestive tract in human defense behavior - structural and functional arguments.
- Author
-
Savulescu-Fiedler I, Gurghean AL, and Siliste RN
- Subjects
- Humans, Neurons physiology, Intestines, Central Nervous System, Gastrointestinal Tract, Enteric Nervous System physiology
- Abstract
The digestive system has an innate monitoring and defense capacity, which allows the recognition and elimination of different dangerous substances. The complex analysis of the intestinal content comprises the cross-interactions between the epithelial cells, the enteroendocrine cells, the neural tissue and the cellular defense mechanisms. The enteric nervous system, also called "the enteric brain" or "the second brain" is the only neuronal network outside the central nervous system capable of autonomous reflex activity. The enteric nervous system activity is mostly independent of the central nervous system, but not in all aspects. In fact, even the enteral reflexes are a consequence of the bidirectional intestine-brain relation. The central nervous and enteric nervous systems are coupled through the sympathetic and parasympathetic branches of the autonomic nervous system. The gastrointestinal functions are regulated due to the interaction between the intrinsic neurons within the gastrointestinal wall and the extrinsic neurons outside the gastrointestinal tract. Here we provide an overview of the important role of the enteric brain in defensive behavior, as well as its structural and functional particularities that make it a special organ., Competing Interests: The authors report no conflict of interest., (©2022 JOURNAL of MEDICINE and LIFE.)
- Published
- 2022
- Full Text
- View/download PDF
5. The Role of Pancreatic Alpha Cells and Endothelial Cells in the Reduction of Oxidative Stress in Pseudoislets.
- Author
-
Wieland FC, Sthijns MMJPE, Geuens T, van Blitterswijk CA, and LaPointe VLS
- Abstract
Pancreatic beta cells have inadequate levels of antioxidant enzymes, and the damage induced by oxidative stress poses a challenge for their use in a therapy for patients with type 1 diabetes. It is known that the interaction of the pancreatic endocrine cells with support cells can improve their survival and lead to less vulnerability to oxidative stress. Here we investigated alpha (alpha TC-1), beta (INS1E) and endothelial (HUVEC) cells assembled into aggregates known as pseudoislets as a model of the pancreatic islets of Langerhans. We hypothesised that the coculture of alpha, beta and endothelial cells would be protective against oxidative stress. First, we showed that adding endothelial cells decreased the percentage of oxidative stress-positive cells. We then asked if the number of endothelial cells or the size (number of cells) of the pseudoislet could increase the protection against oxidative stress. However, no additional benefit was observed by those changes. On the other hand, we identified a potential supportive effect of the alpha cells in reducing oxidative stress in beta and endothelial cells. We were able to link this to the incretin glucagon-like peptide-1 (GLP-1) by showing that the absence of alpha cells in the pseudoislet caused increased oxidative stress, but the addition of GLP-1 could restore this. Together, these results provide important insights into the roles of alpha and endothelial cells in protecting against oxidative stress., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Wieland, Sthijns, Geuens, van Blitterswijk and LaPointe.)
- Published
- 2021
- Full Text
- View/download PDF
6. The Postprandial Glycaemic and Hormonal Responses Following the Ingestion of a Novel, Ready-to-Drink Shot Containing a Low Dose of Whey Protein in Centrally Obese and Lean Adult Males: A Randomised Controlled Trial.
- Author
-
Smith K, Taylor GS, Allerton DM, Brunsgaard LH, Bowden Davies KA, Stevenson EJ, and West DJ
- Subjects
- Adult, Blood Glucose drug effects, C-Peptide blood, Cross-Over Studies, Eating, England, Food, Formulated, Gastric Emptying physiology, Gastric Inhibitory Polypeptide blood, Gastric Inhibitory Polypeptide drug effects, Glucagon blood, Glucagon-Like Peptide 1 blood, Glucagon-Like Peptide 1 drug effects, Humans, Insulin blood, Male, Middle Aged, Obesity, Abdominal blood, Obesity, Abdominal metabolism, Postprandial Period drug effects, Thinness blood, Thinness metabolism, Whey Proteins administration & dosage, Young Adult, Blood Glucose metabolism, Gastrointestinal Hormones metabolism, Obesity, Abdominal diet therapy, Whey Proteins pharmacology
- Abstract
Purpose: Elevated postprandial glycaemia [PPG] increases the risk of cardiometabolic complications in insulin-resistant, centrally obese individuals. Therefore, strategies that improve PPG are of importance for this population. Consuming large doses of whey protein [WP] before meals reduces PPG by delaying gastric emptying and stimulating the secretion of the incretin peptides, glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide 1 [GLP-1]. It is unclear if these effects are observed after smaller amounts of WP and what impact central adiposity has on these gastrointestinal processes., Methods: In a randomised-crossover design, 12 lean and 12 centrally obese adult males performed two 240 min mixed-meal tests, ~5-10 d apart. After an overnight fast, participants consumed a novel, ready-to-drink WP shot (15 g) or volume-matched water (100 ml; PLA) 10 min before a mixed-nutrient meal. Gastric emptying was estimated by oral acetaminophen absorbance. Interval blood samples were collected to measure glucose, insulin, GIP, GLP-1, and acetaminophen., Results: WP reduced PPG area under the curve [AUC
0-60 ] by 13 and 18.2% in the centrally obese and lean cohorts, respectively (both p <0.001). In both groups, the reduction in PPG was accompanied by a two-three-fold increase in GLP-1 and delayed gastric emptying. Despite similar GLP-1 responses during PLA, GLP-1 secretion during the WP trial was ~27% lower in centrally obese individuals compared to lean (p = 0.001). In lean participants, WP increased the GLP-1ACTIVE/TOTAL ratio comparative to PLA (p = 0.004), indicative of reduced GLP-1 degradation. Conversely, no treatment effects for GLP-1ACTIVE/TOTAL were seen in obese subjects., Conclusion: Pre-meal ingestion of a novel, ready-to-drink WP shot containing just 15 g of dietary protein reduced PPG in lean and centrally obese males. However, an attenuated GLP-1 response to mealtime WP and increased incretin degradation might impact the efficacy of nutritional strategies utilising the actions of GLP-1 to regulate PPG in centrally obese populations. Whether these defects are caused by an individual's insulin resistance, their obese state, or other obesity-related ailments needs further investigation., Clinical Trial Registration: ISRCTN.com, identifier [ISRCTN95281775]. https://www.isrctn.com/., Competing Interests: Author LHB was employed by company Arla Foods Ingredients Group P/S (Viby J, Denmark). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Smith, Taylor, Allerton, Brunsgaard, Bowden Davies, Stevenson and West.)- Published
- 2021
- Full Text
- View/download PDF
7. What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?
- Author
-
Kuhre RE, Deacon CF, Holst JJ, and Petersen N
- Subjects
- Animals, Endocrinology methods, Humans, L Cells metabolism, Mice, Research Design, L Cells physiology, Secretory Pathway physiology
- Abstract
Synthetic glucagon-like peptide-1 (GLP-1) analogues are effective anti-obesity and anti-diabetes drugs. The beneficial actions of GLP-1 go far beyond insulin secretion and appetite, and include cardiovascular benefits and possibly also beneficial effects in neurodegenerative diseases. Considerable reserves of GLP-1 are stored in intestinal endocrine cells that potentially might be mobilized by pharmacological means to improve the body's metabolic state. In recognition of this, the interest in understanding basic L-cell physiology and the mechanisms controlling GLP-1 secretion, has increased considerably. With a view to home in on what an L-cell is, we here present an overview of available data on L-cell development, L-cell peptide expression profiles, peptide production and secretory patterns of L-cells from different parts of the gut. We conclude that L-cells differ markedly depending on their anatomical location, and that the traditional definition of L-cells as a homogeneous population of cells that only produce GLP-1, GLP-2, glicentin and oxyntomodulin is no longer tenable. We suggest to sub-classify L-cells based on their differential peptide contents as well as their differential expression of nutrient sensors, which ultimately determine the secretory responses to different stimuli. A second purpose of this review is to describe and discuss the most frequently used experimental models for functional L-cell studies, highlighting their benefits and limitations. We conclude that no experimental model is perfect and that a comprehensive understanding must be built on results from a combination of models., Competing Interests: RK and NP are employed by Novo Nordisk. Novo Nordisk manage had no influence on the conception or content of this review. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Kuhre, Deacon, Holst and Petersen.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.